Go Pro
NASDAQ:BNGO

Bionano Genomics (BNGO) Stock Price, News & Analysis

Bionano Genomics logo
$1.17 -0.04 (-3.31%)
As of 08/28/2026 04:00 PM Eastern

About Bionano Genomics Stock (NASDAQ:BNGO)

Advanced

Key Stats

Today's Range
$1.16
$1.24
50-Day Range
$1.06
$1.25
52-Week Range
$1.00
$5.50
Volume
179,511 shs
Average Volume
150,306 shs
Market Capitalization
$13.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Bionano Genomics, Inc. (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity. These capabilities complement next‐generation sequencing methods by filling critical gaps in detecting large insertions, deletions, inversions, and translocations.

The company’s product portfolio includes the Saphyr instrument, DLS™ (Direct Label and Stain) reagents for consistent labeling performance, and the Bionano Access™ and Bionano Solve™ software suites for data visualization, variant calling and genomic assembly. In addition to direct instrument sales, Bionano offers contract genome mapping services from its service centers, enabling researchers without in-house platforms to access its mapping capabilities. Its customers span academic research institutions, biotechnology and pharmaceutical companies, clinical laboratories and government agencies focused on areas such as cancer genomics, rare disease diagnostics, plant and animal breeding, and translational research.

Founded in 2003 and headquartered in San Diego, California, Bionano Genomics has grown from early development of nanochannel‐based mapping concepts to a commercial enterprise with global reach, serving markets in North America, Europe and the Asia-Pacific region. The company’s leadership team brings together expertise in genomics, engineering and life-science commercialization, guided by President and Chief Executive Officer Erik Holmlin, Ph.D., who has overseen the expansion of the Saphyr platform since its commercial launch in 2017. Bionano continues to advance its technology roadmap with the goal of broadening applications in both research and clinical settings.

AI Generated. May Contain Errors.

Bionano Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

BNGO MarketRank™: 

Bionano Genomics scored higher than 46% of companies evaluated by MarketBeat, and ranked 632nd out of 919 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bionano Genomics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Bionano Genomics has a consensus price target of $6.00, representing about 412.8% upside from its current price of $1.17.

  • Amount of Analyst Coverage

    Bionano Genomics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bionano Genomics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bionano Genomics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bionano Genomics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bionano Genomics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bionano Genomics' valuation and earnings.
  • Percentage of Shares Shorted

    9.86% of the float of Bionano Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bionano Genomics has a short interest ratio ("days to cover") of 8.65.
  • Change versus previous month

    Short interest in Bionano Genomics has recently increased by 8.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bionano Genomics does not currently pay a dividend.

  • Dividend Growth

    Bionano Genomics does not have a long track record of dividend growth.

  • News Sentiment

    Bionano Genomics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Bionano Genomics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for BNGO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Bionano Genomics to their MarketBeat watchlist in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $4,880.00 in company stock, which represents 0.0354% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Bionano Genomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,880.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.65% of the stock of Bionano Genomics is held by insiders.

  • Percentage Held by Institutions

    11.35% of the stock of Bionano Genomics is held by institutions.

  • Read more about Bionano Genomics' insider trading history.
Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNGO Stock News Headlines

Bionano Genomics Earnings Call Shows Growth Amid Constraints
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript
Bionano Genomics Q2 earnings preview
See More Headlines

BNGO Stock Analysis - Frequently Asked Questions

Bionano Genomics' stock was trading at $1.53 at the beginning of the year. Since then, BNGO shares have decreased by 23.5% and is now trading at $1.17.

Bionano Genomics, Inc. (NASDAQ:BNGO) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.03. The firm earned ($6.67) million during the quarter, compared to the consensus estimate of $7.55 million. Bionano Genomics had a negative trailing twelve-month return on equity of 78.78% and a negative net margin of 106.58%.
Read the conference call transcript
.

Bionano Genomics shares reverse split on Monday, January 27th 2025.The 1-60 reverse split was announced on Wednesday, January 22nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Bionano Genomics (BNGO) raised $30 million in an IPO on Friday, September 21st 2018. The company issued 5,500,000 shares at $5.00-$6.00 per share.

Top institutional investors of Bionano Genomics include GSA Capital Partners LLP (1.31%).
View institutional ownership trends
.

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionano Genomics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Waste Connections (WCN), AUO (AUOTY), American Water Works (AWK) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/10/2026
Today
8/29/2026
H.C. Wainwright 28th Annual Global Investment Conference
9/14/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:BNGO
CIK
1411690
Fax
N/A
Employees
300
Year Founded
2002

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+412.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.40 million
Net Margins
-106.58%
Pretax Margin
-106.36%
Return on Equity
-78.78%
Return on Assets
-48.54%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
2.48
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$28.51 million
Price / Sales
0.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.68 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
11,780,000
Free Float
11,700,000
Market Cap
$13.78 million
Optionable
No Data
Beta
1.63

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:BNGO) was last updated on 8/29/2026 by MarketBeat.com Staff.
From Our Partners